Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.850
-0.050 (-2.63%)
At close: Jun 27, 2025, 4:00 PM
1.930
+0.080 (4.32%)
After-hours: Jun 27, 2025, 6:27 PM EDT

Company Description

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease.

The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.

It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025.

Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Ernexa Therapeutics Inc.
Ernexa Therapeutics logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Sanjeev Luther

Contact Details

Address:
1035 Cambridge Street, Suite 18A
Cambridge, Massachusetts 02141
United States
Phone 212 582 1199
Website ernexatx.com

Stock Details

Ticker Symbol ERNA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000748592
CUSIP Number 114082308
ISIN Number US1140822099
Employer ID 31-1103425
SIC Code 2834

Key Executives

Name Position
Sanjeev Luther Chief Executive Officer, President and Director
Sandra M. Gurrola Principal Financial and Accounting Officer and Senior Vice President of Finance
Dorothy J. Clarke General Counsel
Dr. Robert Hamilton Pierce M.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Jun 18, 2025 EFFECT Notice of Effectiveness
Jun 18, 2025 424B3 Prospectus
Jun 12, 2025 8-K Current Report
Jun 11, 2025 SCHEDULE 13D/A Filing
Jun 11, 2025 S-8 Securities to be offered to employees in employee benefit plans
Jun 11, 2025 S-3 Registration statement under Securities Act of 1933
Jun 9, 2025 8-K Current Report
Jun 2, 2025 8-K Current Report
May 15, 2025 SCHEDULE 13G/A Filing
May 15, 2025 SCHEDULE 13G Filing